Physician profile
Kyle Jones
NPI 1639620271
$6,946.28
in general payments reported to CMS, 2019-2025
32 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,067 · 2022: $923 · 2023: $1,479 · 2024: $1,646 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,956.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,116.62 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,098.58 | 2021-2025 | |
| Lilly USA, LLC | $877.44 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $569.42 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $442.81 | 2022-2025 | Freestyle Libre 3, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.45 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.59 | 2022-2025 | Xifaxan |
| Pfizer INC. | $296.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $251.87 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $249.50 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $236.80 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $186.45 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $156.53 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $124.93 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $88.48 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $60.00 | 2021 | |
| Exact Sciences Corporation | $55.19 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $53.89 | 2021 | |
| Amarin Pharma, INC. | $45.29 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $44.27 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $42.63 | 2022 | |
| Evoke Pharma, INC. | $41.90 | 2021-2025 | |
| Genentech USA, INC. | $35.26 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.51 | 2024 | Givlaari |
| Almatica Pharma LLC | $27.32 | 2021 | |
| Corcept Therapeutics | $22.78 | 2025 | Korlym |
| Medtronic, INC. | $18.88 | 2024 | Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $18.13 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.42 | 2025 | |
| Dexcom, INC. | $14.50 | 2023 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $14.31 | 2021 | |
| Esperion Therapeutics, INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.